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Abstract
Background: The Mayo Lung Project (MLP), a randomized controlled clinical trial of lung cancer screening
conducted between 1971 and 1986 among male smokers aged 45 or above, demonstrated an increase in lung
cancer survival since the time of diagnosis, but no reduction in lung cancer mortality. Whether this result
necessarily indicates a lack of mortality benefit for screening remains controversial. A number of hypotheses have
been proposed to explain the observed outcome, including over-diagnosis, screening sensitivity, and population
heterogeneity (initial difference in lung cancer risks between the two trial arms). This study is intended to provide
model-based testing for some of these important arguments.
Method: Using a micro-simulation model, the MISCAN-lung model, we explore the possible influence of screening
sensitivity, systematic error, over-diagnosis and population heterogeneity.
Results: Calibrating screening sensitivity, systematic error, or over-diagnosis does not noticeably improve the fit of
the model, whereas calibrating population heterogeneity helps the model predict lung cancer incidence better.
Conclusions: Our conclusion is that the hypothesized imperfection in screening sensitivity, systematic error, and
over-diagnosis do not in themselves explain the observed trial results. Model fit improvement achieved by
accounting for population heterogeneity suggests a higher risk of cancer incidence in the intervention group as
compared with the control group.
Background
Lung cancer is the leading cause of cancer deaths
among men and women in the United States [1]. Clini-
cal treatment has not led to major improvements in
patients’ survival from lung cancer. Although steps are
being taken to prevent lung cancer incidence, particu-
larly through anti-tobacco public health efforts, consid-
erable time is required to realize a noticeable decrease
in the population incidence of this disease. As a result,
considerable attention has focused on the utility of
screening as a strategy for achieving a reduction in lung
cancer mortality.
The Mayo Lung Project (MLP), a randomized con-
trolled trial including 9211 male cigarette smokers, was
conducted between 1971 and 1983 to assess whether
frequent screening through chest x-rays and sputum
cytology administered every four months for a six-year
period would result in a long-term reduction in lung
cancer mortality. Control group participants received
usual care at the Mayo Clinic, i.e., advice to receive these
screening tests annually. No significant between-group
difference was found in lung cancer mortality, at the end
of the trial as well as at the end of an extended 20 year
follow-up [2], when lung cancer mortality rates were
defined as the number of lung cancer deaths divided by
person-years at risk of death. However, there was a larger
incidence of lung cancer in the screening intervention
group, and those diagnosed with lung cancer in the
screening intervention group did have longer lung cancer
survival from the time of diagnosis than those diagnosed
with lung cancer in the control group [2,3].
Considerable interest has focused on examining possi-
ble explanations for this survival benefit and lack of
mortality benefit. It has been argued that the observed
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survival improvement could be due to some well-known
mechanisms, i. e., over-diagnosis [4], lead-time bias, and
length bias [5]. Other explanations of the MLP results
include: the excess radiation risk received during the
trial could offset the mortality benefit of the screening
group [6]; a survival benefit did exist but was concealed
by higher lung cancer risks in the screening intervention
group [7]; there was not enough statistical power to
demonstrate a mortality benefit due to design of the
trial [3,8], etc. Below we discuss some of those key argu-
ments from a modeling perspective.
Over-diagnosis
Over-diagnosis is the detection of lesions that meet the
pathologic definition of cancer but will never progress
to cause symptoms or death during a patient’s lifetime.
An over-diagnosed cancer, then, is a tumor that can be
screen-detected at preclinical stage II-, but never grows
into III+. Thus, this tumor can never be clinically diag-
nosed until the patient dies from causes other than lung
cancer. In other words, an over-diagnosed cancer is a
tumor that could be detected by screening but will
never cause clinical symptoms. Marcus et al [5] investi-
gated this issue of over-diagnosis in MLP and concluded
that better survival for individuals in the intervention
arm indicates that some lesions with limited clinical
relevance may have been identified in this group. In
other words, the 46 excess cancers identified at the end
of the study were in fact not morbid lesions or were so
indolent that patients with significant health risks (e.g.,
smokers) were more likely to die of other causes before
these cancers became a problem.
Screening sensitivity and systematic negative error
Technological limits of chest X-rays might also have
influenced the trial outcome. If a screening takes place
when lung cancer is at a preclinical stage, there is a
probability of detecting the cancer by the screening test
("test sensitivity”), depending on stage and cell type. In
terms of test sensitivity, chest X-ray does not compare
favorably with more recent screening tools such as spiral
computed tomography (CT). A related concept is the
systematic negative error, i. e., the probability of a sec-
ond false-negative diagnosis given that the previous
diagnosis is false-negative. Systematic errors from
screening tests can occur as a result of person-level
issues, lesion-level issues and timing issues.
Initial difference in cancer risk
Strauss [7] found from the MLP data that exposure to
air pollution was significantly associated with higher
lung cancer incidence and mortality in the control arm
whereas the same exposure predicted lower incidence
and mortality in the screening intervention arm. In
addition, history of bronchitis/pneumonia predicted lung
cancer incidence in the screening intervention arm. The
fact that these associations varied across the trial arms
indicates that there might have been hidden differences
between the two arms, particularly those differences in
confounding variables that the trial did not measure and
failed to balance across the two experimental conditions.
Hence, the hypothesis that the initial lung cancer risk
could be higher in the screening intervention arm than
in the control arm. This hypothesis is also consistent
with the fact that the screening intervention arm had
more lung cancer incidence and lung cancer mortality
while no biomedical evidence of over-diagnosis of lung
cancer has been confirmed in this trial.
Newer technologies such as spiral computed tomogra-
phy (CT) have been shown to identify early lung cancer
lesions [9] and may prove to be a more useful screening
modality than chest x-rays. However, if lung cancer
lesions with little or no clinical relevance exist, CT will
likely identify them at an even higher rate than would
have occurred through use of the traditional chest x-ray.
The sensitivity of newer technologies can have consider-
able clinical implications, underscoring the importance
of gaining a better understanding of the plausibility of
hypotheses such as sensitivities, over-diagnosis and
initial difference in data from large scale trials such as
the MLP. In this paper, we explore the relevance of
over-diagnosis and initial difference hypotheses with a
microsimulation approach, as well as the relevance of
two screening parameters: test sensitivity and systematic
negative error.
Methods
MISCAN is a microsimulation model for the early
detection of chronic diseases, where a large number of
individual life histories are stochastically generated to
simulate chronic disease progressions [10]. The MIS-
CAN-lung cancer model has been developed to main-
tain a comprehensive surveillance of population trends
in lung cancer and to estimate the impact of cancer
control interventions [11]. In MISCAN-lung, the disease
progression includes the following phases: initiation of
cells, clonal expansion of initiated cells, malignant trans-
formation, and progression to diagnosis. Preclinical lung
cancer can pass through a number of disease stages,
each with a specific dwelling time distribution, before a
clinical diagnosis takes place. Stage distribution depends
on transition probabilities to diagnosis versus progres-
sion to next disease state. In pre-invasive stages we use
continuous growth by cell clone. When it turns into
invasive cancer, we start to model the growth by dis-
crete stages.
We calibrate the cancer incidence to the observed
results from the Mayo Lung Project, while the onset of
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pre-clinical screen-detected cancer follows a Weibull
distribution with its shape and mean parameters based
upon the age and cell type-specific cancer incidence in
the Surveillance, Epidemiology, and End Results (SEER)
program. For the impact of screening, we specify an
exponentially distributed sojourn time for the preclinical
disease state (with the mean parameter calibrated to
trial results), as earlier studies [12,13] have shown that
the exponential distribution for the preclinical state pro-
vides a good fit to cancer incidence and prevalence. We
simulate three separate pathways to clinical diagnosis
for squamous, adeno/large cell, and small cell lung can-
cers. Each pathway starts with undetectable preclinical
Stage I and can develop into screen-detectable Stage II.
Or, the tumor can be clinically diagnosed in Stage III.
The cancers that develop further are diagnosed as Stage
IV, when the tumor will have metastasized. In other
words, we assume that preclinical lung cancer can only
be screen-detected while clinical lung cancer can be
both screen-detected and clinically detected.
Our model specifies the screening policy and atten-
dance pattern, as well as characteristics of screening
tests, and for this study the subjects in the intervention-
arm are simulated to receive screenings every four
months for six years. The sensitivity of a screening test
depends on the preclinical disease state (categorized by
stage and cell type). If a lung cancer is detected by
screening during the preclinical phases, the time of diag-
nosis is earlier than in the situation without screening.
Thus the stage at diagnosis could be Stage I or II (to be
referred to as “stage II-” hereinafter) at screen-detection,
instead of Stage III or IV (to be referred to as “stage III
+” hereinafter) at clinical diagnosis.
A diagram for the model flow is given in Figure 1 and
a list of parameters used in MISCAN-lung is provided
in Additional File 1.
We explore over-diagnosis and initial risk difference as
possible explanations for the observations from the MLP,
as well as the potential effectiveness of using more sensi-
tive screening technologies. First, we model the impact of
Stage II screening sensitivity and Stage III screening
sensitivity, i.e., the probability of the positive result condi-
tional on being in preclinical screen-detectable Stage II
and the probability of the positive result conditional on
being in screen-detectable Stage III. Next, we add a
related parameter, systematic negative error. That is, if a
cancer is missed through screening during the sojourn
time there is an increase in the probability that the same
cancer will be missed again at a next screening during
the sojourn time. We term this incremental probability
as systematic negative error.
We first set sensitivity parameters to be 1 and sys-
tematic negative error parameters to be 0 (Simple
Model in Additional File 2), and obtain a deviance
measure by subtracting the log likelihood of the esti-
mated model from the log likelihood of the saturated
model and multiplying the result by 2. We apply a c2
test to the resulting deviance measure as a test of good-
ness of fit. We then fit for sensitivity parameters and set
systematic negative error to zero (Sensitivity Model in
Additional File 2) to see if this model outputs a deviance
value significantly lower than the deviance measure
from the Simple Model. Next, we set sensitivity para-
meters to be 1 and fit for the systematic negative error
parameters (Systematic Error Model in Additional
File 2) to test their effect on reducing the deviance. We
then fit for both sensitivity parameters and systematic
negative error parameters in order to test their joint
effect (Sensitivity-Error Model in Additional File 2). For
over-diagnosis in our study, we introduce a parameter
for indolent cancers. If fitting this indolent cancer
parameter does not decrease the deviance measure from
our Simple Model, then the simulation result is incon-
sistent with an assumption of serious over-diagnosis
(Over-diagnosis Model).
Finally, we test the hypothesis of differential lung can-
cer risks between the intervention group and the control
group (Risk Difference Model) by calibrating a differ-
ence factor of lung cancer onset probability between the
two trial arms. All previous models assumed that the
lung cancer onset probability was the same between two
trial arms, while this Risk Difference Model fits for a
difference factor for the lung cancer onset probability.
In other words, the Risk Difference Model allows the
two trial arms to differ in their initial lung cancer risk.
For the risk difference hypothesis, we also examined the
participant’s behavior to identify smoking status at the
beginning of the intervention, running an independent
t-test to compare the number of cigarettes smoked per
day between the screening intervention arm and the
control arm.
Results
Additional File 2 lists the parameters fitted in our six
different models. Predicted results from the Simple
Model and observed results are summarized in Addi-
tional File 3, which shows that the Simple Model
achieved a deviance measure of 23.45. While 90 screen-
detected lung cancers and 116 otherwise diagnosed lung
cancers were observed in the screening intervention
arm, the Simple Model expects 88.1 screen-detected
lung cancers and 99.7 otherwise diagnosed ones.
A binomial test shows that the observed number of lung
cancers in the screening intervention arm was signifi-
cantly higher (p = 0.016) than what was expected by the
Simple Model.
Additional File 4 summarizes the deviance reduction, a
measure of how much the model has improved from the
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Simple Model to all of the other five models. The Sensitiv-
ity Model, where we fitted for sensitivity parameters at
stage II- and stage III+, optimizes the sensitivity values to
be 0.967 for stage II- and 0.995 for stage III+. The Sensi-
tivity Model however did not substantially improve the
model prediction from model 1, with a reduction of the
deviance measure by 1.27 (Δdf = 1, p = 0.23).
In the Systematic Error Model we obtained fitted
values of 0.022 and 0.185. This model moderately
decreases the deviance from 23.54 in the Simple Model
to 21.4, which implies that the systematic error para-
meter did not significantly affect the observed results
(ΔDev = 2.14, Δdf = 1, p = 0.14). The Sensitivity-Error
Model further added screening sensitivities as fitting
parameters to the Systematic Error Model but did not
improve the model prediction significantly (the deviance
measure is 21.4 in Systematic Error Model vs. 21.38 in
Sensitivity-Error Model). The comparison between the
Simple Model and the Sensitivity Model, as well as the
comparison between the Systematic Error Model and
the Sensitivity-Error Model, indicate that the sensitivity
parameters did not contribute significantly to the model
improvement.
Our Over-diagnosis Model included the indolent
cancer parameters in the model and found minimal
deviance reduction (ΔDev = 0.07, Δdf = 1, p = 0.79).
Our Risk Difference Model allows for the initial risk dif-
ference between the intervention groups and control
groups and reduced the deviance from 23.54 in the Sim-
ple Model to 18.5, and thereby achieved the smallest
deviance measure among all six models (ΔDev = 5.04,
Δdf = 1, p = 0.02). Finally, with respect to smoking
behavior at baseline, we found a clinically small but sta-
tistically significant between-group difference in number
of cigarettes smoked per day, with screening interven-
tion group subjects on average smoking .53 more cigar-
ettes per day than subjects in the control group (t =
2.09, p = 0.03).
Discussion and Conclusion
New screening technologies could focus on features that
could detect tumors of smaller sizes, or they could focus
on features that increase screening sensitivity within the
current range of screen-detectable tumor sizes. If fitting
the sensitivity measures had increased the model’s pre-
diction of observed lung cancer incidence by cell type
and stage for both groups, we would expect that emer-
ging technologies with higher screening sensitivity mea-
sures could achieve improved mortality outcomes.
However, the Sensitivity Model, Systematic Error Model,
and Sensitivity-Error Model did not substantially
improve the fit from what had been achieved by the
Simple Model. The implication is that the hypothesized
imperfections in screening sensitivity alone could not
have explained the lack of mortality benefit in the Mayo
Lung Project. Thus, in evaluating the priorities of devel-
oping new screening technologies for lung cancer, it
might be advisable to focus more on the features that
could potentially lower the detectable threshold rather
than on features that increase screening sensitivity
Figure 1 A Diagram for the Model Flow of MISCAN-Lung.
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within the current range of screen-detectable tumor
sizes.
The failure of our Over-diagnosis Model to signifi-
cantly improve the fit from the Simple Model also leads
us to conclude that over-diagnosis is not likely to be a
serious issue in MLP. This confirms the observation
that over-diagnosis bias is minimal in screen-detected
lung cancers in the case of chest radiograph examina-
tion [14]. However, findings from studying MLP chest
X-ray screening in the 1970 s do not necessarily imply
that over-diagnosis is an irrelevant consideration for
emerging technologies such as spiral computed tomo-
graphy. Inasmuch as CT detects smaller tumors than do
chest X-rays, there may well be more chances for the
former to give false positive results and thus produce
artificially “better” lung cancer survival through over-
diagnosis. The plausibility of over-diagnosis of lung
cancer diagnosis when using newer, more sensitive
screening technologies can be tested using the MISCAN
micro-simulation model we used here, so long as the
modeler has access to a similar set of input parameters.
The significant improvement achieved by the Risk Dif-
ference Model suggests that there might have been an a
priori higher risk of cancer incidence in the intervention
than in the control group, i. e., the mortality benefit
from screening was concealed by the higher lung cancer
risk in the intervention group. This is consistent with
the view that population heterogeneity could have
played a role in the trial outcomes [15]. However, Mar-
cus and Prorok [16] showed that adjustment for four
lung cancer risk factors (age at entry, history of cigarette
smoking, exposure to non-tobacco lung carcinogens, or
previous pulmonary illnesses) did not alter the original
findings of the Mayo Lung Project. Another explanation
could be that there might have been a coincidental
imbalance in the percentages of small cell lung cancer
between the two trial arms, since small cell lung carci-
noma progresses much faster than the majority of non-
small cell lung carcinoma cases, and thus a different
proportion of small-cell cases would be very likely to
result in different mortality outcomes [17].
Although we find a statistically significant difference
in the number of cigarettes smoked per day, there is no
documented evidence that a difference of one half of a
cigarette a day will make a significant difference in
health outcomes. Rather, this difference might have
reflected a “volunteer effect” [18] since in MLP only
those randomized to the screening intervention group
were asked about their consent to participate in the
trial. Ideally, the trial’s randomization process should
have occurred after rather than before the baseline pre-
valence screening, since the prevalence screening could
have created behavioral differences between the two
trial arms.
Despite the significant improvement in model fit
achieved by the Risk Difference Model, from the per-
spective of model parsimony our Simple Model might
still be the best choice from among all six models dis-
cussed here, especially if we seek to extend MISCAN to
simulations of other lung cancer screening programs
that do not suffer from suboptimal randomization of
subjects to experimental condition.
Finally, in considering the utility of interventions for
preventing chronic diseases, the effectiveness of screen-
ing and testing programs should not be measured only
in terms of the extent to which earlier detection can
achieve earlier treatment. Rather, as Huuskonen [19]
proposed, screening should be viewed as a coordinated
intervention with the goal of identifying populations at
risk and modifying that risk. Counseling and pharmaco-
logical interventions have been added to screening inter-
ventions in lung cancer detection programs [20,21].
Meanwhile, as reduced risk for this disease may begin as
early as five years after smoking cessation, evaluation of
the lung cancer screening program will be complete
only when the trial subjects’ smoking behavior is mea-
sured on at least an annual basis. Insufficient informa-
tion about changes in smoking behavior among MLP
trial subjects after the six-year intervention limits the
investigation of long-term behavioral differences
between the two trial arms. Current and future clinical
trials of the impact of lung cancer screening on mortal-
ity should incorporate measurement of smoking beha-
vior at regular follow-up intervals into their data
collection process.
In this study, modeling was used to try to represent
our knowledge of the system of interaction between the
biological and screening processes. While we have, in
principle, full knowledge of the screening processes
because these are designed by people, we are less confi-
dent about our model’s ability to represent the biological
processes. A large part of the biological processes were
not observed, in this case particularly because detection
of a cancer triggered interventions that made it impossi-
ble to determine whether the cancer was indolent after
all. Modeling is one way to learn some more about the
underlying biological processes in a more indirect way.
This study investigated a number of hypotheses that
have been raised in the literature. The true hypothesis
may not be among them. Moreover, the hypotheses that
have been raised in the literature are generally not spe-
cified exactly therefore we were left to make some arbi-
trary assumptions, e.g. to define what is exactly the
behavior of an indolent cancer. Also, this study has only
looked at the main effects of risk difference and over-
diagnosis on incidence outcome, i.e., these parameters
were mainly considered as single factors rather than fac-
tors that could interact with other parameters to
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influence the outcome. If large population datasets for
cancer screening become available, it will be interesting
for future studies to examine the possible interaction
effects of sensitivity and risk difference, systematic error
and risk difference, or a possible three-way interaction
of sensitivity-systematic error-risk difference.
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